REBOOT Inotropes

Inotropes serve as essential tools for modulating cardiac contractility in critically ill patients, functioning through distinct adrenergic and non-adrenergic pathways. These agents—including dobutamine, epinephrine, milrinone, and calcium—differ significantly in their effects on chronotropy, systemic vascular resistance, and pulmonary vascular resistance, necessitating precise selection based on patient physiology. Effective management requires integrating physical exam findings, biomarkers, and point-of-care ultrasound to guide therapy, particularly in complex scenarios like cardiogenic shock, Takotsubo cardiomyopathy, and BRASH syndrome. While catecholamines like epinephrine provide potent support for bradycardia and shock, phosphodiesterase inhibitors like milrinone offer distinct advantages in heart failure by reducing afterload without inducing significant tachycardia. Ultimately, successful hemodynamic optimization relies on a dynamic approach of measuring, intervening, and reassessing, ensuring that the chosen inotrope aligns with the patient's specific hemodynamic profile and underlying pathology.